Conavi Medical Corp.

As of June 30, 2026, Conavi Medical Corp. carries a market capitalization of 14.59M, placing it among publicly traded companies globally. Its enterprise value stands at 25.15M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Conavi Medical Corp.'s next confirmed earnings release is scheduled for December 17, 2026.

As of June 30, 2026, Conavi Medical Corp. has 103.49M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 24.14, and the price-to-book ratio stands at -1.21.

These figures are as of June 30, 2026. The EV/Sales ratio of 48.26 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 25.15M versus a market cap of 14.59M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Conavi Medical Corp. maintains a current ratio of 0.21, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -92.18, indicating conservative leverage, while an interest coverage ratio of -22.30 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -155.50, reflecting losses generated across the asset base. The company generates approximately 11,329.46 in revenue per employee across its workforce of 46.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.29 indicates how many times Conavi Medical Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Conavi Medical Corp.'s stock has declined approximately 68.51% over the past 52 weeks. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.16.

Over the twelve months ended June 30, 2026, Conavi Medical Corp. generated 521,155.08 in revenue and converted that into -12.71M in net income, yielding earnings per share of -0.14. EBITDA reached -12.55M, while operating income came in at -13.08M.

As of June 30, 2026, Conavi Medical Corp. holds 545,208.39 in cash and equivalents against 11.10M in total debt, resulting in a net debt position of 10.11M. Total book value stands at -12.04M, with working capital of -11.15M providing operational flexibility.

Conavi Medical Corp. produced -11.51M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -452,078.90 in capital expenditures, free cash flow totaled -11.96M - equivalent to -0.13 per share.

Over the twelve months ended June 30, 2026, Conavi Medical Corp. posted a gross margin of 96.09, reflecting its pricing power and cost economics. The operating margin of -2,508.99 and net profit margin of -2,439.76 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -95.07: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -38.01, meaning Conavi Medical Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Conavi Medical Corp.'s most recent stock split took place on October 16, 2024 with a 25:1 split ratio.

As of June 30, 2026, Conavi Medical Corp. has an Altman Z-Score of -50.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.